Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium-Reference-Cited by-同舟云学术

Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium

Published:2023-06-24 Issue:11 Volume:29 Page:1693-1705
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Wong Serre-Yu¹,Wellens Judith²,Helmus Drew¹,Marlow Luke³,Brann Stephanie³,Martinez Pazos Vicky¹,Weinberg Alan⁴,Moran Hunter R¹,McGregor Colleen³,Vermeire Séverine²,Watanabe Kenji⁵,Kamikozuru Koji⁵,Ahuja Vineet⁶,Vermani Shubi⁶,Lindsay James O⁷,Kingston Ashley⁷,Dutta Usha⁸,Kaur Harmandeep⁸,Silverberg Mark S⁹,Milgrom Raquel⁹,Chien Ng Siew¹⁰,Mak Joyce Wing Yan¹⁰,Cadwell Ken¹¹¹²¹³,Thompson Craig¹⁴,Colombel Jean-Frédéric¹,Satsangi Jack³,Ambrose Tim¹⁵,Brain Oliver¹⁵,Walsh Alissa¹⁵,Klenerman Paul¹⁵,Travis Simon¹⁵,Edmans Matthew¹⁵,Dixon Rebekah¹⁶,Navalurkar Reema¹⁷,Gold Stephanie¹⁶,Lacoste Joshua¹⁶,Chen Clara¹⁸,Halfvarson Jonas¹⁹,Bergemalm Daniel¹⁹,Rubin David T²⁰,Abreu Maria T²¹,Allez Matthieu²²,Anne Neil Jessica²³,Sota Stela²³,Ku Jang Kyung²³,Ching Krystal²³,Venzon Mericien²³,Yao Xiaomin²³,Bernard Lucie²³,Cowger Tori L²⁴,Accorsi Emma²⁴,Wiseman Dean¹⁶,Riggs Alexa¹⁶,Stanley Stephanie¹⁶,Reyes-Mercedes Pamela¹⁶,Mendiolaza Michelle¹⁶,Nunez Sara¹⁶,Phillipe Brianne¹⁶,Chen Xin¹⁶,Tankelevich Michael¹⁶,Jimenez Darwin¹⁶,Ramos Julio¹⁶,Kedia Saurabh⁶,Yokoyama Yoko²⁵,Kawai Mikio²⁵,Sato Toshiyuki²⁵,Kojima Kentaro²⁵,Nagase Kazuko²⁵,Nakamura Shiro²⁵,Miyazaki Takako²⁵,Kakimoto Kazuki²⁵,Kamata Noriko²⁵,Hosomi Shuhei²⁵,Nishishita Masakazu²⁵,Chan Alicia²⁶,Sharma Vishal⁸,Singh Kumar Anupam⁸,Samanta Jayanta⁸,Shah Jimil⁸,Sinha S K⁸,Cipriano Bessie²⁷,Lee Irish²⁷,Ruocco Giuseppe²⁷,Garcia Nicole²⁰,Choi Natalie²⁰,Alejandra Quintero Maria²¹,

Affiliation:

1. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY , USA

2. Department of Gastroenterology and Hepatology, Leuven University Hospitals , Leuven , Belgium

3. Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford , Oxford , United Kingdom

4. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai , New York, NY , USA

5. Center for Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine , Nishinomiya , Japan

6. Department of Gastroenterology, All India Institute of Medical Sciences , New Delhi , India

7. Center for Immunobiology, Blizard Institute, Queen Mary University of London – Barts Health NHS Trust , London , United Kingdom

8. Postgraduate Institute of Medical Education and Research , Chandigarh , India

9. Division of Gastroenterology, Department of Medicine, Mount Sinai Hospital, University of Toronto , Toronto, Ontario , Canada

10. Division of Gastroenterology and Hepatology, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong , China

11. Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine of the University of Pennsylvania , Pennsylvania, PA , USA

12. Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine of the University of Pennsylvania , Pennsylvania, PA , USA

13. Department of Pathology and Laboratory Medicine, Perelman School of Medicine of the University of Pennsylvania , Pennsylvania, PA , USA

14. Division of Biomedical Sciences, Warwick Medical School, University of Warwick , Warwick , United Kingdom

15. Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford , Oxford , UK

16. The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York , USA

17. University of Washington , Washington , USA

18. Department of Medicine, Stony Brook University Hospital , Stony Brook, New York , USA

19. Örebro University Hospital , Örebro , Sweden

20. University of Chicago Inflammatory Bowel Disease Center , Chicago , USA

21. University of Miami , Miami , USA

22. Assistance Publique, Hopitaux De Paris, Hopital Saint-Louis , Paris , France

23. Department of Microbiology, New York University Grossman School of Medicine , New York , USA

24. Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, MA , USA

25. Center for Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine , Japan

26. Division of Gastroenterology and Hepatology, The Chinese University of Hong Kong - Prince of Wales Hospital , Hong Kong

27. Center for Immunobiology, Blizard Institute, Queen Mary University of London - Barts Health NHS Trust , London , UK

Abstract

Abstract Background Beyond systematic reviews and meta-analyses, there have been no direct studies of serological response to COVID-19 in patients with inflammatory bowel disease (IBD) across continents. In particular, there has been limited data from Asia, with no data reported from India. The ICARUS-IBD (International study of COVID-19 Antibody Response Under Sustained immunosuppression in IBD) consortium assessed serological response to SARS-CoV-2 in patients with IBD in North America, Europe, and Asia. Methods The ICARUS-IBD study is a multicenter observational cohort study spanning sites in 7 countries. We report seroprevalence data from 2303 patients with IBD before COVID-19 vaccination between May 2020 and November 2021. SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies were analyzed. Results The highest and lowest SARS-CoV-2 anti-spike seropositivity rates were found in Asia (81.2% in Chandigarh and 57.9% in Delhi, India; and 0% in Hong Kong). By multivariable analysis, country (India: odds ratio [OR], 18.01; 95% confidence interval [CI], 12.03-26.95; P < .0001; United Kingdom: OR, 2.43; 95% CI, 1.58-3.72; P < .0001; United States: OR, 2.21; 95% CI, 1.27-3.85; P = .005), male sex (OR, 1.46; 95% CI, 1.07-1.99; P = .016), and diabetes (OR, 2.37; 95% CI, 1.04-5.46; P = .039) conferred higher seropositivity rates. Biological therapies associated with lower seroprevalence (OR, 0.22; 95% CI, 0.15-0.33; P < .0001). Multiple linear regression showed associations between anti-spike and anti-nucleocapsid titers with medications (P < .0001) but not with country (P = .3841). Conclusions While the effects of medications on anti-SARS-CoV-2 antibody titers in patients with IBD were consistent across sites, geographical location conferred the highest risk of susceptibility to serologically detectable SARS-CoV-2 infection. Over half of IBD patients in India were seropositive prior to vaccination. These insights can help to inform shielding advice, therapeutic choices, and vaccine strategies in IBD patients for COVID-19 and future viral challenges.

Funder

Chandigarh Institutional Ethics Committee

Digestive System in Children and Adults

Postgraduate Institute of Medical Education and Research

All India Institute of Medical Sciences Institute

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

https://academic.oup.com/ibdjournal/advance-article-pdf/doi/10.1093/ibd/izad097/50698140/izad097.pdf

Reference42 articles.

1. COVID-19 vaccine strategies must focus on severe disease and global equity;McIntyre;Lancet,2022

2. SARS-CoV-2 vaccination in IBD: past lessons, current evidence, and future challenges;Wellens;J Crohns Colitis,2021

3. Impact of medications on COVID-19 outcomes in inflammatory bowel disease: analysis of over 6,000 patients from an international registry;Ungaro;Gastroenterology.,2022;162(1):316-319.5

4. The epidemiology of inflammatory bowel disease: East meets west;Mak;J Gastroenterol Hepatol.,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab;Scientific Reports;2024-01-02